ATE228832T1 - System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung - Google Patents

System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Info

Publication number
ATE228832T1
ATE228832T1 AT95912170T AT95912170T ATE228832T1 AT E228832 T1 ATE228832 T1 AT E228832T1 AT 95912170 T AT95912170 T AT 95912170T AT 95912170 T AT95912170 T AT 95912170T AT E228832 T1 ATE228832 T1 AT E228832T1
Authority
AT
Austria
Prior art keywords
drugs
blood
diagnostic
bbb
nanoparticles
Prior art date
Application number
AT95912170T
Other languages
English (en)
Inventor
Joerg Kreuter
Dimitri A Karkevich
Bernhard Sabel
Renad N Alyautdin
Original Assignee
Nanopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanopharm Ag filed Critical Nanopharm Ag
Application granted granted Critical
Publication of ATE228832T1 publication Critical patent/ATE228832T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95912170T 1994-02-28 1995-02-28 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung ATE228832T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20332694A 1994-02-28 1994-02-28
PCT/EP1995/000724 WO1995022963A1 (en) 1994-02-28 1995-02-28 Drug targeting system, method for preparing same and its use

Publications (1)

Publication Number Publication Date
ATE228832T1 true ATE228832T1 (de) 2002-12-15

Family

ID=22753510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912170T ATE228832T1 (de) 1994-02-28 1995-02-28 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Country Status (10)

Country Link
US (1) US6117454A (de)
EP (1) EP0740548B1 (de)
JP (1) JP2930421B2 (de)
AT (1) ATE228832T1 (de)
AU (1) AU1947395A (de)
CA (1) CA2184242C (de)
DE (1) DE69529054T2 (de)
ES (1) ES2188652T3 (de)
HU (1) HUT75469A (de)
WO (1) WO1995022963A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US7425543B2 (en) * 1992-11-16 2008-09-16 The Corporation Of Mercer University Microencapsulated materials and method of making same
EP0805678B1 (de) * 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
EP0920339A2 (de) * 1996-07-09 1999-06-09 The Johns Hopkins University System zur freigabe genetischen materials
DE19648663A1 (de) * 1996-11-14 1998-05-28 Schering Ag Flüssigkeitsgefüllte Mikropartikel mit neuem Wirkungsprinzip und deren Verwendung als Diagnostika und Therapeutika
DE19648664A1 (de) * 1996-11-14 1998-05-28 Schering Ag Wirkstoffhaltige Mikropartikel, diese enthaltende Mittel, deren Verwendung zur ultraschallgesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu deren Herstellung
AU3176097A (en) * 1997-06-13 1998-12-30 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
EP1100475A1 (de) * 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Verwendung von arzneistoffbeladenen nanopartikel zur behandlung von krebs
IL150374A0 (en) * 1999-12-23 2002-12-01 Neurochem Inc Compounds and methods for modulating cerebral amyloid angiopathy
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
DE10118852A1 (de) * 2001-04-17 2002-10-31 Fricker Gert Bdellosomen
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
DE10164871B4 (de) * 2001-02-23 2006-08-10 Umarex Sportwaffen Gmbh & Co Kg Handfeuerwaffe
US6867275B2 (en) * 2001-03-30 2005-03-15 Rohm And Haas Company Solid media
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20030092029A1 (en) 2001-06-06 2003-05-15 Lee Josephson Magneitc-nanoparticle conjugates and methods of use
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
EP1458361A4 (de) * 2001-11-20 2007-04-25 Advanced Inhalation Res Inc Zusammensetzungen zur abgabe von produkten mit anhaltender wirkung
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
WO2003077886A1 (en) * 2002-03-20 2003-09-25 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
WO2004043218A2 (en) 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
CA2492807A1 (en) * 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ
US7112620B2 (en) * 2002-10-18 2006-09-26 Albright Robert L Hemocompatible polymer systems & related methods
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US20050084513A1 (en) * 2003-10-21 2005-04-21 Board Of Regents Nanocoating for improving biocompatibility of medical implants
US8642455B2 (en) * 2004-02-19 2014-02-04 Matthew R. Robinson High-throughput printing of semiconductor precursor layer from nanoflake particles
US8329501B1 (en) 2004-02-19 2012-12-11 Nanosolar, Inc. High-throughput printing of semiconductor precursor layer from inter-metallic microflake particles
US7306823B2 (en) * 2004-09-18 2007-12-11 Nanosolar, Inc. Coated nanoparticles and quantum dots for solution-based fabrication of photovoltaic cells
US8309163B2 (en) * 2004-02-19 2012-11-13 Nanosolar, Inc. High-throughput printing of semiconductor precursor layer by use of chalcogen-containing vapor and inter-metallic material
US8846141B1 (en) 2004-02-19 2014-09-30 Aeris Capital Sustainable Ip Ltd. High-throughput printing of semiconductor precursor layer from microflake particles
US8372734B2 (en) 2004-02-19 2013-02-12 Nanosolar, Inc High-throughput printing of semiconductor precursor layer from chalcogenide nanoflake particles
US8623448B2 (en) * 2004-02-19 2014-01-07 Nanosolar, Inc. High-throughput printing of semiconductor precursor layer from chalcogenide microflake particles
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
ITTO20040124A1 (it) * 2004-03-01 2004-06-01 Medestea Internaz Srl Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative
DE502005001579D1 (de) * 2004-04-05 2007-11-08 Basf Ag Wirkstoffhaltige polymerteilchen
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
DE602005012289D1 (de) * 2004-09-14 2009-02-26 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
EP1661559A1 (de) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Verabreichungssystem hergestellt durch ein Miniemulsionsverfahren
WO2007011396A2 (en) 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
WO2006056362A2 (en) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Delivery vehicle manufactured by the miniemulsion method
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1743643A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Neue Darreichungsformen substituierter Pyrazolinverbindungen
AU2006284832B2 (en) 2005-08-31 2011-06-02 T2 Biosystems Inc. NMR device for detection of analytes involving magnetic particles
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US8215961B2 (en) 2005-12-15 2012-07-10 Posit Science Corporation Cognitive training using visual sweeps
US8197258B2 (en) 2005-12-15 2012-06-12 Posit Science Corporation Cognitive training using face-name associations
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20080019921A1 (en) * 2006-06-30 2008-01-24 Invitrogen Corporation Uniform fluorescent microsphere with hydrophobic surfaces
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US7773097B2 (en) 2006-10-05 2010-08-10 Posit Science Corporation Visual emphasis for cognitive training exercises
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
US8849372B2 (en) * 2006-11-22 2014-09-30 The General Hospital Corporation Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent
US7540615B2 (en) 2006-12-15 2009-06-02 Posit Science Corporation Cognitive training using guided eye movements
US9114127B2 (en) * 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
US8802184B2 (en) * 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
WO2009026164A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Magnetic resonance-based viscometers and methods
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
EP2070521A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanopartikel mit modifizierter Oberfläche
PE20091265A1 (es) * 2007-12-13 2009-09-18 Univ Kyushu Nat Univ Corp Nanoparticulas que contienen pioglitazona
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
US20120114706A1 (en) * 2008-05-08 2012-05-10 Dipak Kumar Sarkar Endorphin Therapy Compositions and Methods of Use Thereof
WO2009137109A1 (en) * 2008-05-08 2009-11-12 Rutgers, The State University Endorphin therapy compositions and methods
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
CA2738855A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2010040173A1 (en) * 2008-10-08 2010-04-15 Commonwealth Scientific And Industrial Research Organisation A method of delivering functional agents across the blood-brain barrier
HRP20192259T1 (hr) * 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
JP5725884B2 (ja) * 2011-01-27 2015-05-27 理研ビタミン株式会社 経口用製剤
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9149426B2 (en) * 2012-02-15 2015-10-06 University Of Tennessee Research Foundation Nanoparticle composition and methods to make and use the same
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
SG10201705121PA (en) * 2012-12-21 2017-07-28 Advanced Medical Frontier Co Ltd Composition and food or drink
US9308445B1 (en) 2013-03-07 2016-04-12 Posit Science Corporation Neuroplasticity games
US9598377B2 (en) 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
US9561192B2 (en) * 2013-06-28 2017-02-07 The Board Of Trustees Of The University Of Illinois Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
KR101576204B1 (ko) * 2014-03-04 2015-12-09 서울대학교산학협력단 PoP 나노구조체 및 이를 이용한 약물 전달 방법
KR101635373B1 (ko) * 2014-08-20 2016-07-04 연세대학교 산학협력단 공액 고분자 나노 입자 및 이의 제조 방법
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
WO2022023450A1 (en) 2020-07-28 2022-02-03 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic raf inhibitors
JP2023535790A (ja) 2020-07-28 2023-08-21 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式ｒａｆ阻害薬及びその使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957662A (en) * 1972-08-08 1976-05-18 Hoffmann-La Roche Inc. Pharmaceutical lubricants
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5756423A (en) * 1980-09-19 1982-04-05 Akio Hagiwara Agent for local administration
US4880816A (en) * 1982-05-18 1989-11-14 University Of Florida Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
US5187158A (en) * 1982-05-18 1993-02-16 University Of Florida Brain-specific drug delivery
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0545913B1 (de) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Abgabesysteme für Arzneimittel
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1989004671A1 (en) * 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Differential delivery of therapeutic agents across the blood brain barrier
US4866042A (en) * 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5059415A (en) * 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
CA2025907A1 (en) * 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
WO1991016064A1 (en) * 1990-04-13 1991-10-31 The Rockefeller University Methods and compositions for reversibly permeabilizing the blood brain barrier
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition

Also Published As

Publication number Publication date
JP2930421B2 (ja) 1999-08-03
ES2188652T3 (es) 2003-07-01
DE69529054T2 (de) 2003-08-21
US6117454A (en) 2000-09-12
WO1995022963A1 (en) 1995-08-31
CA2184242A1 (en) 1995-08-31
EP0740548A1 (de) 1996-11-06
CA2184242C (en) 2000-05-02
HUT75469A (en) 1997-05-28
HU9602356D0 (en) 1996-10-28
EP0740548B1 (de) 2002-12-04
DE69529054D1 (de) 2003-01-16
AU1947395A (en) 1995-09-11
JPH09506109A (ja) 1997-06-17

Similar Documents

Publication Publication Date Title
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
Kelley et al. Dopamine and conditioned reinforcement: I. Differential effects of amphetamine microinjections into striatal subregions
Kramlinger et al. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression
ATE261721T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DK0862416T3 (da) Ikke-polymert indgivelsessystem med forhalet frigørelse
ATE204468T1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
EP1466606A3 (de) Verwendung von Inosine zur Herstellung eines Medikamentes zur Stimulierung des Axonwachstums von ZNS-Neuronen
HUP9902553A2 (hu) Mikrocseppekből álló propofol készítmények
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
ES2196092T3 (es) Composicion antibacteriana liposomica, de baja rigidez.
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
Levy et al. An evaluation of the anticonvulsant effects of vitamin E
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
Gombos et al. Long-term enhancement of entorhinal-dentate evoked potentials followingmodified'ECS in the rat
Kreuter et al. Drug targeting to the nervous system by nanoparticles
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties